Aspira Women's Health Inc. · OTC:AWHL
Aspira Women's Health — Vermillion — Investor Presentation (January 2016)
36 slides from Aspira Women's Health's investor presentation, Jan 11, 2016
Slide 1: Informatic Solutions to Personalize Gynecologic Disease Management
(2 VERMILLION’ Informatic Solutions to Personalize Gynecologic Disease Management $4 ty SO ASPIRA LABS JANUARY 2016 ‘YOUR HEALTH. OUR PASSION.
Slide 2: Forward-Looking Statements
QVERMILLION" FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will
Slide 3: Company Overview
Company Overview ° Ticker Symbol: VRML (NASDAQ CM) ¢ Market Cap (12-21-2015): $91.0M - Shares Outstanding (10-31-2015): 52.0M ¢ Cash and Cash Equivalents (9-30-2015): $24.0M ¢ Enterprise Value: $67.0M LQVERMILLION' eas ventan ne Ag tae 3
Slide 4: Vermillion's Focus is Gynecologic Health
Vermillion’s Focus is Gynecologic Health To be the global leader in personalized medical management of gynecologic health to improve clinical comes for patients, physicians and payers ‘ To aid clinicians in diagnosing women with pelvic mize their care and ultimately save lives, while improving the q
Slide 5: Investment Highlights
Investment Highlights * First of its kind, FDA-cleared multi-variate technology platform * Target market expanding to >$1 billion with the OVA family of products* * New Management Team in place * Key investor support from Jack W. Schuler and Oracle Investment Management * February 2015 — ASPiRA sale
Slide 6: Vermillion Has a Large Market Opportunity
Vermillion Has a Large Market Opportunity Benign US healthcare system annually Mass S€°" Non-Gyn spends $22B on endometriosis Hasislosde — care’, $5.1B on Ov Ca care? and cyst $1.2B on PCOS care? benign’ Ovarian } Ovarian ; Pelvic : Pelvic Pelvic Cancer } Cancer ? Masses { Masses Diseases Deaths = 3
Slide 7: Ovarian Cancer - The Size of the Problem
Ovarian Cancer - The Size of the Problem Ovarian cancer stage at presentation and survival 5-Year Incidence Survival Stagel | I Confined to the ovary 23% 90% Extends to true pelvis 13% 80% Extends beyond the true pelvis 47% 15-20% Distant disease 16% <5% >60% of ovarian cancers are diagnosed at late
Slide 8: Despite This Unmet Clinical Need...
Despite This Unmet Clinical Ne ..-no solution exists. Current standard of care is inadequate to manage patients and results in poor outcomes and increased costs Clinical findings are inadequate... © Physical exam is specialist-dependent ¢ Imaging is subjective ..as are commonly used biomarkers © CA-
Slide 9: Vermillion's Solution
Vermillion’s Solution Ova An FDA-cleared liquid biopsy test, which pre-operatively assesses risk of ovarian cancer and helps triage high risk patients The OvaCalc® algorithm combines five biomarker results into a single numerical “test value” related to the probability of malignancy Interpret OVA1 o
Slide 10: Vermillion's Solution: How It is Used in Practice
Vermillion’s Solution: How It is Used in Practice After Protocol: Before Protocol: Survey 96% cancer detction QVERMILLION Z
Slide 11: Vermillion's Solution: How It is Used in Practice
Oa Vermillion’s Solution: How It is Used in Practice Or QVERMILLION'
Slide 12: OVA1 vs Standard of Care
(A1°® vs Standard of Care Q VERMILLION
Slide 13: 85% Reduction
85% Reduction - 23% 50% 0% CA125-II* Clinical Modified OVA1 OVA1 + Assessment*? ACOG** Clinical Assessment™
Slide 14: Key Publications
Key Publications Author, ‘Conel le ‘etiee onclusions Effectiveness of amultvarate Ualend, etal. gq) * Fist etal ial of OVANY n= $90 smal University + OVAI detacted 76% of malignancies missed by CA-125 Bisoperstve oF Kentucky _pationts assessment of «= The performance of OVA wes consistent in early-
Slide 15: Publications Drive Standard of Care/Reimbursement
Publications Drive Standard of Care/Reimbursement iblished Evidence Guidelines Payers Ueland, et al. Obstetrics and Gynecology, 2011 Ne <€ Medicare Bristow, et al. Gynecologic Oncology, 2013 Society of Gynecologic Longoria, et al. Oncology ‘Am J Obstet Gynecol, 2013 “se Position Statements Goodrichr
Slide 16: Intellectual Property
Intellectual Property Strong IP Protection a * Issued patents covering various ovarian cancer biomarkers ¢ Pending patent applications covering OVA1® and Overa® products Algorithm - kept as trade secret QVERMILLION
Slide 17: Continuing Product Development
Continuing Product Development Improvement to OVA1's biomarker technology is expected soon... Cva® = Qvera Increased specificity and positive predictive value (PPV), maintaining the sam s 1 NPV as OVA1, more accurately assorting patients for r Expected to be launched in early 2016
Slide 18: Overa - Breakthrough in Ovarian Cancer Management
Overa® - Breakthrough in Ovarian Cancer Management || Sensitivity | Specificity | PPV | NPV 92% 54% 31% 97% (85.1-96.3) (48.6-58.3) (26.0-37.0) (93.6-98.5) Equal Equal Veracyte* Afirma 92% 52% 32-47% 93-96% QVERMILLION
Slide 19: We Save More Lives and Reduce More Cost
We Save More Lives and Reduce More Cost By Evolving Our Strategy To radically imprc classifying all f patient care, we have expanded our scope by Ivic mass patients to determine the best disease management care path 500K to 1M pelvic masses diagn Correct referral fc rect treatment ovarian cancer sur
Slide 20: Build on Our Foundation
Build on Our Foundation To impact this expanded scope, biomarkers alone are limited in terms of needed algorithm development and accuracy Unparalleled Data Registry ei) ral 9 Imaging/ : Clinical Data iran ocahues Biomarkers zg Algorithm Platform QVERMILLION’
Slide 21: Building on Our Foundation - Our Expertise
g on Our Foundation - Our Exp’ OVA SERIES tb IMAGING Vv FDA Vv Proof of concept studies V Biomarkers V Algorithm development V Multi-center studies VIP ——" PROVEN =» COMPETENCIES QVERMILLION
Slide 22: 250K - 1M TAM
250K - 1M TAM Rule out; watc surgical choi progression, recurr monitoring 100K - 300K TAM Guided referral $440M - $880M $67M - $200M
Slide 23: The Value of Vermillion
The Value of Vermillion To Patients (ama) To Providers MY To Payers QVERMILLION® 62015 Vermin ne. igh Rater olution for all Customers « Improve time to Tx * Low risk: peace of mind * High risk: get to the right specialist * Improved differential Dx © Low risk: keep patient ¢ High risk: refer to Gyn
Slide 24: Product Pipeline of ASPiRA Labs
Product Pipeline of ASPiRA Labs Product | ovat? | Overa | Overan | OVAt | DxA | DxA2 | =a Propoeiion Rule-out, surgical Rule-out, surgical speaist specaist ‘pathway cholce, ‘pathway chotce, Dxor referral referral progression progression" endometriosis Market size! 100-300K 100-300K 250K-1M 250K-1M >
Slide 25: International
INTERNATIONAL Top down, high-touch approach to IDNs, systems, ACOs Bottom uplow-touch approach to patients, providers — WVDSenice Offering —> *Overa® platform: Roche Cobas 6000 (10,000 installed worldwide) according to itto:/www. cobas,com/home/product/clinical-and-immunochemistry-testing/cobas-6000
Slide 26: Commercialization Strategy
Commercialization Strategy Payer strategy to increase utilization and average unit price Bn a Seen ease ASEIRA Labs sepisnel lly Sofie referral base (eee tegen Wb ibe fe atient date) Ss / : Hospital stable revenue OB/Gyn Systems / (Customer Account Menagers and Market Development Specialists) Region
Slide 27: OVA1 Coverage YTD - Patient Lives in Millions
OVA1® Coverage YTD - Patient Lives in Millions Goal: Targeted Growth with Positive Coverage Decisions Target: 2 National 7 Payor 2U = Pots) mo Michigan 4 Arkansas Novitas Rivers ai LQVERMILLION — c2:s verter i red 27
Slide 28: Cost Effectiveness Model Analysis
Cost Effectiveness Model Analysis ICER OvaA1* ASPiRA ~$1,495 $12,189/QALY' ovat** ASPIRA ~$1,495 $35,094/QALY" BRCA1/2 Myriad Genetics ~$4,040 $36,845/QALY* Oncotype DX Genomic Health ~$4,175 $15,578/QALY? Threshold to be considered cost effective $50,000/QALY Incromental cost-affectiveness ratio (I
Slide 29: Experienced Management Team in Place
Experienced Management Team in Place Title Experience Valet Palit President and CEO Duanon.gsiems_ LabCorp oe : Donald Munroe, PhD. Cre stintine Offer Zecca | coniye Invitrogen Psanner MDAnderson Judith Wolf, M.D. Chief Medical Officer Ee Set antes Laura Miller SVR Sales Castors Eiparense @HealthTro
Slide 30: 2015 Achievements / 2016 Anticipated Milestones
2015 Achievements / 2016 Anticipated Milestones U Overa® FDA submission - March 6,2015 Quest settlement and testing services agreement - March 11, 2015 Strategic partnership and quality benchmarking study with Kaiser Permanente (Southem California) announced - April 14, 2015 Disclose Overa data (ASC
Slide 31: -QVERMILLION®
-QVERMILLION® ¢ Price (maintain / build value) ¢ Sales ramp / penetration (build on existing market share / call point) ¢ Margins (>80% over 2016 - 2019) e Reimbursement - revenue cycle management 31
Slide 32: Vermillion Expects to Be a Market Leader by 2020 / Anticipated Milestones
Vermillion Expects to Be a Market Leader by 2020 / Anticipated Milestones Volume maltpiors regional lab One See ot validation Studies Ovetapue anticipatory sudies —imaging, {CGN sco, sar ‘Ova symptomindex, ASCO, ACOG HECON, guidelines DxA DxA Overa® — — ———_ validation HECON deared studies studies v
Slide 33: Sustainable Advantages, Tailwinds and Headwinds
Sustainable Advantages, Tailwinds and Headwinds Advantages ¢ Biomarker IP Trade secret algorithm ¢ ASPiRA Labs data structure and source Tailwinels * FDA process experience * Robust clinical / health economics publication pipeline © World-class clinical Headwints ¢ Payer contracting — driving rigoro
Slide 34: Vermillion's Strategy: Built for the Future
Vermillion’s Strategy: Built he Future at VRML/ FDA-cleared product Unique Category 1 CPT code (AMA) Medicare Coverage/Gap Fill Pricing IVD kit CLIA lab for LDTs Multi-modal predictive analytics Proprietary disease registry/samples Leading peer-reviewed publications QQ KR KNX JNA KN KNX JNA XR KN NN
Slide 35: Conclusions
Conclusions ¢ First of its kind, FDA-cleared multi-variate technology platform ¢ In two pivotal trials, OVA1® detected >80% cancers missed by clinical assessment'* ¢ Market leader expertise: biomarkers, algorithm development and clinical/data partnering to develop solutions ¢ Risks mitigated - Stron
Slide 36: Corporate Headquarters and Investor Relations
QVeRMILL Corporate Headquarters 12117 Bee Caves Rd. Building III, Suite 100 Austin, TX 78738 Tel: (512) 519.0400 Fax: (512) 439.6980 Investor Relations Michael Wood LifeSci Advisors LLC Tel: (646) 597 6983 [email protected]